Response to letter to the editor "It's time to consider a new topical algorithm for psoriasis"
- PMID: 37821054
- DOI: 10.1016/j.jaad.2023.08.109
Response to letter to the editor "It's time to consider a new topical algorithm for psoriasis"
Keywords: general dermatology; psoriasis; roflumilast; tapinarof; topical corticosteroids; topical therapy.
Conflict of interest statement
Conflicts of interest Dr Menter served as an investigator for AbbVie, Amgen, Boehringer Ingelheim, Celgene Corporation, Janssen Pharmaceuticals, Merck & Co, Inc, Novartis Pharmaceuticals Corp, and Pfizer Inc and received grants/research funding; served as an investigator for UCB and received honoraria; served as a consultant for AbbVie, Amgen, Eli Lilly and Company, Janssen Pharmaceuticals, Inc, Leo Pharma, US, Novartis, UCB, and Wyeth Labs and received honoraria; served as a consultant for Valeant Pharmaceuticals North and received fees; served as a speaker for AbbVie, Amgen, Ali Lilly and Company, Janssen Biotech, Leo Pharma, US, Sun Pharmaceutical Industries Ltd, UCB, and Wyeth Labs and received honoraria; served as an advisory board member for AbbVie, Amgen, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Leo Pharma, US, and Medscape and received honoraria; served as an advisory board member for Mindera and received fees; and served as an advisory board member for Afecta Pharmaceuticals and received no compensation. Drs Elmets and Malik and author Castillo have no conflicts of interest to declare.
Comment on
-
It is time to consider a new topical algorithm for psoriasis.J Am Acad Dermatol. 2024 Feb;90(2):e84-e85. doi: 10.1016/j.jaad.2023.07.1048. Epub 2023 Oct 7. J Am Acad Dermatol. 2024. PMID: 37813190 No abstract available.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
